ServierOfficial website ↗Being free to make our own decisions enables us to fulfil our vocation as a Group committed to therapeutic progress to serve patient needs. Source: https://servier.com/en/servier-group1 medicine explainedivosidenibTibsovoIDH1 inhibitorTibsovo (ivosidenib) is an oral targeted therapy from Servier for acute myeloid leukaemia carrying an IDH1 mutation. It blocks the mutant enzyme's abnormal product, letting blocked blood cells mature again, alone or with azacitidine.Some acute myeloid leukaemias carry a mutation in the IDH1 gene. The mutant enzyme produces an abnormal substance, 2-hydroxyglutarate, that prevents y
